[go: up one dir, main page]

MX2007012624A - Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a. - Google Patents

Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.

Info

Publication number
MX2007012624A
MX2007012624A MX2007012624A MX2007012624A MX2007012624A MX 2007012624 A MX2007012624 A MX 2007012624A MX 2007012624 A MX2007012624 A MX 2007012624A MX 2007012624 A MX2007012624 A MX 2007012624A MX 2007012624 A MX2007012624 A MX 2007012624A
Authority
MX
Mexico
Prior art keywords
receptor complex
benzimidazole derivatives
modulating
gabaa receptor
compounds
Prior art date
Application number
MX2007012624A
Other languages
English (en)
Inventor
Lene Teuber
Philip K Ahring
Elsebet Ostergaard Nielsen
Janus S Larsen
Naheed Mirza
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of MX2007012624A publication Critical patent/MX2007012624A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invencion se relaciona con nuevos derivados de benzimidazol, con composiciones farmaceuticas que contienen estos compuestos y con metodos de tratamiento con los mismos. Los compuestos de la invencion son utiles en el tratamiento de enfermedades y trastornos del sistema nervioso central, los cuales responden a la modulacion del complejo del receptor GABAA, y en particular para combatir la ansiedad y enfermedades relacionadas.
MX2007012624A 2005-04-13 2006-04-07 Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a. MX2007012624A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67064705P 2005-04-13 2005-04-13
DKPA200500530 2005-04-13
PCT/EP2006/061417 WO2006108800A1 (en) 2005-04-13 2006-04-07 Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
MX2007012624A true MX2007012624A (es) 2008-01-11

Family

ID=36658703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012624A MX2007012624A (es) 2005-04-13 2006-04-07 Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.

Country Status (19)

Country Link
US (1) US7851490B2 (es)
EP (1) EP1877052B1 (es)
JP (1) JP2008535891A (es)
KR (1) KR20070119691A (es)
AU (1) AU2006233894A1 (es)
CA (1) CA2604516A1 (es)
CO (1) CO6241194A2 (es)
DE (1) DE602006007976D1 (es)
DK (1) DK1877052T3 (es)
ES (1) ES2330468T3 (es)
HR (1) HRP20090453T1 (es)
IL (1) IL185371A0 (es)
MX (1) MX2007012624A (es)
NO (1) NO20075793L (es)
NZ (1) NZ560939A (es)
PL (1) PL1877052T3 (es)
PT (1) PT1877052E (es)
RU (1) RU2405779C2 (es)
WO (1) WO2006108800A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080077620A (ko) 2005-12-05 2008-08-25 뉴로서치 에이/에스 벤즈이미다졸 및 ｇａｂａａ 수용체 복합체를 조절하기위한 이의 용도
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
WO2010055125A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055124A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055126A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
RU2452486C1 (ru) * 2011-04-13 2012-06-10 Общество с ограниченной ответственностью "Лечебно-реабилитационный научный центр "Феникс" Способ фармакотерапии панического расстройства

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CN1072669C (zh) 1995-04-21 2001-10-10 纽罗研究公司 苯并咪唑化合物及其用作gabaa受体复合物调节器的用途
EP0934281B1 (en) * 1996-10-21 2010-01-06 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as baga- a? receptor modulators
JP2001519429A (ja) 1997-10-10 2001-10-23 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール化合物、この化合物を含む医薬組成物、およびそれらの使用
WO2000078728A1 (en) * 1999-06-22 2000-12-28 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
AU2002221566A1 (en) * 2000-12-20 2002-07-01 Neurosearch A/S Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
EP1613618A2 (en) 2003-04-03 2006-01-11 Neurosearch A/S BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX
EP1613312B1 (en) * 2003-04-03 2008-02-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gaba a receptor complex
US7521448B2 (en) * 2003-08-21 2009-04-21 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-Kit inhibitors
EP1678144A1 (en) 2003-10-23 2006-07-12 Akzo Nobel N.V. 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX
AU2005312028A1 (en) * 2004-12-01 2006-06-08 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途

Also Published As

Publication number Publication date
RU2405779C2 (ru) 2010-12-10
WO2006108800A1 (en) 2006-10-19
AU2006233894A1 (en) 2006-10-19
PL1877052T3 (pl) 2010-01-29
PT1877052E (pt) 2009-08-25
EP1877052B1 (en) 2009-07-22
JP2008535891A (ja) 2008-09-04
US20090036493A1 (en) 2009-02-05
RU2007137096A (ru) 2009-05-20
EP1877052A1 (en) 2008-01-16
ES2330468T3 (es) 2009-12-10
HRP20090453T1 (hr) 2009-10-31
CA2604516A1 (en) 2006-10-19
DE602006007976D1 (de) 2009-09-03
DK1877052T3 (da) 2009-10-12
KR20070119691A (ko) 2007-12-20
US7851490B2 (en) 2010-12-14
NZ560939A (en) 2010-07-30
NO20075793L (no) 2008-01-14
IL185371A0 (en) 2008-02-09
CO6241194A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3
WO2004087690A3 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
NO20075793L (no) Benzimidazolderivater og deres anvendelse for modulering av GABAA - reseptorkomplekset
GB0611907D0 (en) Compounds
UA104861C2 (uk) Похідні хроману як модулятори trpv3
ATE386519T1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren
UA91998C2 (ru) Производные бензимидазола и их использование для модулирования рецепторного комплекса гамка
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
EA201190003A1 (ru) Производные хроменона в качестве trpv3 антагонистов

Legal Events

Date Code Title Description
FG Grant or registration